RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-30. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
=== β-α-β motif === Due to the chirality of their component amino acids, all strands exhibit right-handed twist evident in most higher-order β-sheet structures. In particular, the linking loop between two parallel strands almost always has a right-handed crossover chirality, which is strongly favored by the inherent twist of the sheet. This linking loop frequently contains a helical region, in which case it is called a β-α-β motif. A closely related motif called a β-α-β-α motif forms the basic component of the most commonly observed protein tertiary structure, the TIM barrel.
== Meat == In butchery and gastronomy, the epimysium is often called silverskin, and is thought of as a kind of gristle. It remains tough, chewy, and inedible when cooked, and is often trimmed away before cooking.
The Mkhedrioni were subsequently given responsibility for rooting out "Zviadists" in western Georgia, which they did with a brutal efficiency that was widely criticised by foreign governments and international human rights organisations. Shevardnadze responded by gradually limiting the organisation's power. Although Ioseliani remained head of the supposedly civilianised organisation, it continued to function as a private army. In early 1995, Shevardnadze ordered it to disarm, accusing it of deep involvement in organised crime. He narrowly escaped assassination in a bomb attack on August 29, 1995, which he blamed on a shadowy coalition of "mafia forces" including Ioseliani and others. Other acts of political violence were also blamed on the Mkhedrioni. The organisation was outlawed and Ioseliani imprisoned, although many regarded the claim that it had been involved in the bombing as being inconclusively proven. In spite of its banning, the Mkhedrioni continues to have a somewhat shadowy existence in Georgian politics. A number of members, led by Tornike Berishvili, recreated it in 1999 as an ostensibly political rather than paramilitary organisation. It has been claimed that the Mkhedrioni has had relations with Chechen separatists and continues to be involved in criminal and paramilitary activities, including continued guerrilla attacks in Abkhazia. Jaba Ioseliani was released from prison in an amnesty in April 2000 and resumed his post as head of the Mkhedrioni, declaring his intention to run for president and participate in the November 2003 parliamentary elections.
Sources: en.wikipedia.org
==== 1993–1997 ==== Under Bill Clinton (President 1993–2001) and P. V. Narasimha Rao (Prime Minister 1991–1996) both sides mishandled relations, according to Arthur G. Rubinoff. Clinton simultaneously pressured India to liberalize its economy while criticizing New Delhi on human rights and nuclear issues. In the face of criticism from Washington and opposition at home, Indian leaders lost their enthusiasm for rapprochement and reverted to formalistic protocol over substantive diplomacy. The Brown Amendment that restored American aid to Pakistan in 1995 was an irritant. In returning to a Cold War style rhetoric, Indian parliamentarians and American congressmen demonstrated their unwillingness to establish a new relationship.
=== Underdiagnosis === Despite increasing clinical documentation, symptomatic Tarlov cysts remain frequently underdiagnosed. This has been attributed to persistent misconceptions in clinical practice and the common perception that these cysts represent incidental findings. Radiologists often omit documenting them on MRI reports or describe them as clinically insignificant, which may contribute to delayed or missed diagnoses. Smaller cysts, in particular, are more likely to be overlooked.
==== Huo and Wang ==== In 1989–1993, Huo and Wang (中国社会科学院考古研究所, Zhongguo shehui kexueyuan kaogu yanjiusuo) tested the following caves: 224, 76, 4, 8, 34, 68, 77, 98, 104, 114, 117, 118, 119, 125, 129, 135, 162, 171, 180, 189, 196, 198, 206, 212, 219, 227, 27, 39, 48, 60, 69, 84, 91, 92, 99, 123, 139, 161, 165, 178, 207. They proposed a chronology which has some significant differences with the chronology previously proposed by Su Bai. Japanese teams of Nagoya University (日本名古屋大学) tested in 1995, 1997, 1998 and 2011 the following caves: 8, 171, 224, 13, 67, 76, 77, 92, 205. Many of the results remain inconclusive, sometimes even contradictory, and the historical period in question is rather too short in relation to the uncertainty margin of Carbon 14 datation, to provide a meaningful segmentation of the caves. Most narrow Carbon dates given for the Kizil Caves refer to a 68% probability level (1σ), which implies a significant level of uncertainty, and when dates are adjusted to the 95% probability level (2σ) as standard archaeological practice requires, then the timespan between the earliest and lowest dates becomes so large (about 200 to 300 years), as to make individual comparisons between the caves meaningless. Most researchers now use an approach combining artistic and architectural analysis together with carbon-dating, as a way to approach a reliable nomenclature, as proposed by Marylin Martin Rhie from 2001.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.